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Abstract
Objectives—The endopeptidase matrix metalloproteinase-9 (MMP-9) is implicated in
atherosclerotic plaque rupture. We investigate prospective associations between MMP-9 and MI or
stroke in an older general population cohort, accounting for established and novel cardiovascular
risk factors.
Methods—Baseline serum MMP-9 was measured in incident MI (n = 368) and stroke (n = 299)
cases and two controls per case, ‘nested’ in prospective studies of 4252 men and 4286 women
aged 60–79 years, sampled from General Practices in Britain in 1998–2000, with 7-year follow-up
for fatal and non-fatal MI and stroke.
Results—Geometric mean MMP-9 was 528 ng/mL (IQR 397, 743) in MI cases compared to
501 ng/mL (IQR 370, 743) in controls, p = 0.10. Participants in the top compared to bottom third
of MMP-9 levels had an age-adjusted odds ratio for MI of 1.53 (95% CI 1.09, 2.13), which
attenuated to 1.18 (95% CI 0.81, 1.70) after adjustment for established and novel cardiovascular
risk factors. There was weak evidence that OR differed according to pre-existing CVD; the OR for
MI in 187 participants with pre-existing CVD was 2.20 (1.04, 4.64) and 1.24 (0.84, 1.82) in 715
participants without (LR test for interaction p = 0.06). Geometric mean MMP-9 levels were higher
in stroke cases than controls; 522 ng/mL (IQR 363, 673) vs 487 (IQR 393, 704), p = 0.045;
however adjustments similarly attenuated the associations.
Conclusions—While serum MMP-9 is univariately associated with risk of MI and stroke, it is
not a strong independent risk marker for either.
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Abbreviations
MMP-9, matrix metalloproteinase-9; MI, myocardial infarction; CVD, cardiovascular disease;
CHD, coronary heart disease; OR, odds ratio; IQR, inter-quartile range; CI, confidence interval;
CRP, C-reactive protein; IL-6, interleukin-6; BMI, body mass index; SBP, systolic blood pressure;
DBP, diastolic blood pressure; t-PA, tissue plasminogen activator; LR, likelihood ratio
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1 Introduction
Experimental evidence suggests that matrix metalloproteinase-9 (MMP-9) may play a causal
role in new-onset cardiovascular disease (CVD). MMP-9 may contribute to weakening and
rupture of atherosclerotic plaques. MMP-9 (also known as gelatinase B, 92 kDa collagenase)
is one of a family of endopeptidase enzymes involved in the degradation and re-organisation
of the extra-cellular matrix which is involved in vascular remodeling; inappropriate or
absent remodeling can promote atherosclerosis or restenosis [1]. MMPs are expressed in
cells including macrophages, endothelial cells and vascular smooth muscle cells and have
been identified in the shoulder area of human plaques where MMPs may promote the
fibrous cap to weaken, destabilizing the plaque [2].
Despite the experimental evidence, few epidemiologic studies have investigated associations
between MMP-9 and myocardial infarction (MI) or stroke onset. Most have exclusively
studied patients with existing CVD [3–6]. Among these, the Atherogene study reported
elevated risk of CVD mortality (n = 97 deaths) which was completely attenuated by
adjustment for classical risk factors and inflammatory markers [3]. Yet smaller studies did
not report significant associations with CHD risk (n < 65 cases), although type 2 error due to
the small sample size may account for this [4,5]. Another study of patients with carotid
stenosis reported elevated risk of onset of ipsilateral stroke or cardiovascular death (n = 53
cases) but did not account for inflammatory markers [6]. Little evidence exists about
MMP-9 and CVD onset from population studies; the only prospective study of healthy
individuals is a study based on a different subset of the cohort of men investigated here
when they were middle aged, and reported modest positive associations between serum
MMP-9 levels and MI onset (n = 465 cases), but associations were mediated by factors
associated with MMP-9; notably cigarette smoking and inflammatory markers CRP and IL-6
[7]. Evidence from genetic studies about the role of MMP-9 in CVD is mixed [3,8–11].
We have therefore examined associations between MMP-9 and MI and stroke in two
prospective population-based studies of older men and women, taking account of a range of
established and novel cardiovascular risk factors, particularly inflammatory markers CRP
and IL-6. We investigate whether the associations differ between participants with evidence
of pre-existing CVD (MI and stroke) and the healthy population, as previous studies have
not addressed this question. We also investigate whether associations differ between
smokers and non-smokers given the higher burden of atherosclerosis in non-smokers and
previous findings that MMP-9 is higher in smokers [3,7].
2 Methods
In 1998–2000, 4252 men from a single General Practice in each of 24 British towns who
were already participating in a prospective study of CVD ongoing since 1978–1980,
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attended for follow-up measurements at the age of 60–79 years (response rate 77%) [12]. In
1999–2001, a parallel study of 4286 women of the same age and in the same Practices was
established, omitting two study towns (Dewsbury and Maidstone) and adding one other
(Bristol) [13]. Near identical study protocols were used. In both studies, nurses administered
questionnaires, made physical measurements (weight, height and seated blood pressure),
recorded an ECG and collected fasting venous blood samples, from which serum was stored
at ≤−70 °C for subsequent analysis of lipids, hemostatic and inflammatory markers as
described elsewhere [12–15]. MMP-9 (ng/mL) was measured in 2007 using a commercially
available sandwich ELISA (R&D Systems, Oxon, UK) (intra-assay CV 4.4%, inter-assay
CV 10.4%) by researchers blinded to case–control status of samples. In two study towns,
MMP-9 was measured in 138 men in 1996 and again in 2000, to enable intra-individual
comparisons of values over time [16]. Participants completed detailed questionnaires. Pre-
existing CVD was defined from validated reports from General Practitioner, or self-report of
MI or stroke at any questionnaire between 1978–1980 and 1998–2000 in men and in the
baseline questionnaire (1999/2000) in women [12]. Data on cigarette smoking, alcohol
consumption, physical activity, own longest-held occupation (or husband's occupation for
non-married women, coded using the Registrar General's classification) were self-reported.
Region of residence was recorded for women in 1998–2000 and for men at the start of their
follow-up in 1978–1980. Participants were followed-up for 6.25–8.5 years for mortality and
cardiovascular morbidity, with a follow up loss of <2%. Fatal cases were ascertained
through National Health Service Central Registers from a death certificate: ICD-9 codes
410–414 for MI and ICD-9 codes 430–438 for stroke, indicating deaths with cerebrovascular
disease as the underlying cause. Non-fatal MI or stroke was diagnosed using World Health
Organisation diagnostic criteria based on validated reports from General Practitioners,
supplemented by regular reviews of General Practice records [12,17]. Participants provided
written informed consent to the investigation and ethical approval was provided by all
relevant local research ethics committees.
We established a nested case–control study based on all 390 MI cases occurring between
examination date (1998–2000) and June 2006 in men and between examination date (1999–
2001) and September 2007 in women. 780 controls “frequency matched” to cases on town
of residence, gender and age in 5-year bands were randomly selected from among subjects
who survived to the end of the study free from incident CVD. Similar methods were used to
establish a separate nested case–control study based on 324 cases of stroke and 648
(different) frequency matched controls.
2.1 Statistical analyses
Highly skewed variables were transformed using natural logarithms and baseline (age 60–79
years) characteristics of the MI case and control populations were calculated (mean and
standard deviation, median and IQR for skewed variables, or n (%) for categorical
variables). Continuous variables were adjusted for gender, region of residence and age.
Tertiles of MMP-9 were defined separately in the MI and stroke control samples.
Associations between tertiles of MMP-9 and covariables were examined using one-way
ANOVA. Unmatched logistic regression analyses were used to examine associations
between tertiles of MMP-9 and MI. Models were adjusted for cardiovascular risk factors
selected a priori: (i) gender, age and region of residence; (ii) smoking status (current, ex,
never); (iii) history of diabetes, or CHD, social class (manual or non-manual), alcohol use
(1–2 drinks/day or other) physical activity (more or less than 3 h of moderate/vigorous
activity per week), systolic and diastolic blood pressure (SBP and DBP), body mass index
(BMI), total and HDL cholesterol as continuous variables; (iv) CRP and IL-6. Linear
regression models of continuous MMP-9, log transformed to base 2 were used to assess the
effect of a doubling of MMP-9 level on MI. Differences in the MMP-9-CVD associations
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were tested using likelihood ratio (LR) tests for interactions by gender, age, pre-existing
CHD and current smoking status. With 302 MI cases available for the multivariate analyses,
we had 80% power to detect a relative risk of 1.66 in the top tertiles of MMP-9 compared to
the bottom tertiles, at the 5% statistical significance level, assuming two controls per case.
For the 237 stroke cases, the equivalent relative risk was 1.79. Rosner's method was used to
calculate regression dilution ratios on a subset of men with repeated MMP-9 measurements,
using a linear regression model of the repeat measurement predicted by the first
measurement [18].
3 Results
3.1 MI
Baseline characteristics of MI cases and controls are shown in Table 1. MMP-9 levels were
available for 368 of 390 MI cases (270 men and 98 women aged on average 70.8 years) and
for 713 of 780 controls. Cases had higher prevalences of pre-existing CVD (MI or stroke)
and diabetes than controls, were more likely to smoke cigarettes and less likely to be
physically active or light drinkers (all p < 0.02) and had higher mean SBP, total cholesterol,
triglycerides, insulin, glucose, CRP, IL-6, lower HDL cholesterol and forced expiratory
volume (FEV1) and similar SEP, BMI and DBP. Geometric mean serum MMP-9 was 5%
higher (95% CI 4%, 6%) in the MI cases than the controls; 527 ng/mL (IQR 397, 743)
compared to 501 ng/mL (IQR 3670, 743), p (no difference) = 0.096.
3.2 Stroke
MMP-9 data were available for 304 of 324 stroke cases (194 men and 110 women, mean age
71.4 years) and 596 of 648 controls. Characteristics of stroke cases and controls are shown
in Table 1. Cases had higher prevalence of pre-existing CVD and current smokers than
controls (both p < 0.003), but similar SEP, alcohol use, physical activity and prevalence of
pre-existing diabetes. Cases had higher mean blood pressure, total cholesterol, IL-6 and
white blood cell count, but lower FEV1 and similar BMI, HDL, triglyceride, insulin,
glucose, CRP and fibrinogen to controls. MMP-9 levels were 7% (95% CI 5%, 9%) higher
among the stroke cases than the controls; 522 ng/mL (IQR 363, 673) compared to 487 ng/
mL (IQR 393, 704), p (no difference) = 0.045.
3.3 Baseline correlates of MMP-9
Table 2 summarises the associations between MMP-9 and other markers of CVD risk across
thirds of the MI control population (the larger control population). Associations in the stroke
control population were similar unless specifically noted. MMP-9 levels were higher in men
and in smokers, but did not vary with age, social class or other behavioural factors, BMI or
BP. MMP-9 was inversely associated with FEV1. Weak inverse associations with lipids did
not reach conventional levels of statistical significance in the MI control population,
although did in the stroke control population (p < 0.02 for total and HDL cholesterol).
MMP-9 was positively associated with CRP and IL-6. Correlations between log MMP-9 and
covariates were all r < 0.3 (e.g. r = 0.27 for CRP and r = 0.28 for IL-6, p < 0.001).
3.4 Association of MMP-9 with risk of MI
The odds ratio (OR) for MI associated with the highest compared to the lowest third of
MMP-9 and adjusted for age, gender and region of residence (model 1) was 1.53 (95% CI
1.09, 2.13) with a linear trend across the tertiles (p = 0.01) (Table 3). Adjustment for
cigarette smoking (model 2) attenuated the OR to 1.40 (95% CI 0.99, 1.97), p (trend) 0.049.
Further adjustments for established risk factors and for IL-6 and CRP (models 3 and 4)
completely attenuated the OR and linear trend. A doubling of MMP-9 level adjusted for age,
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gender and region of residence (model 1) was associated with an OR for MI 1.20 (95% CI
0.97, 1.48), which was further reduced by adjustments.
There was no evidence that associations between MI and tertiles of MMP-9 or log2 MMP-9
varied by age, gender, or cigarette smoking status (LR tests p > 0.12). The OR for MI for a
doubling of MMP-9 was 1.10 (95% CI 0.86, 1.40) in men and 1.54 (1.00, 2.37) in women.
There was weak evidence that the association may differ according to pre-existing CVD
status, LR test p = 0.06. In the 715 participants without CVD, the OR for MI in the top
compared to bottom third of MMP-9 adjusted for age, gender and region was 1.24 (95% CI
0.84, 1.82), linear trend p = 0.281 (Table 3). The equivalent OR for MI in the 187
participants with pre-existing CVD was 2.20 (1.04, 4.64), linear trend, p = 0.02. The OR was
little changed on full adjustment (Table 3).
3.5 Association of MMP-9 with risk of stroke
No significant associations between MMP-9 and stroke were observed in multivariate
regression models (Table 4) in sample with or without pre-existing CVD and there was no
evidence for interaction between by pre-existing CVD (Table 4), gender, age or cigarette
smoking (LR tests all p > 0.22).
3.6 Impact of adjustment for regression dilution ratio
A regression dilution ratio of 0.46 (95% CI 0.32, 0.60) was calculated in a subset of 138
men with MMP-9 levels measured 4 years apart [16]. The OR of MI among men in the top
third of MMP-9 compared with the lowest third and adjusted for age, gender and region,
lipids, BMI and behavioural risk factors (model 3), corrected for regression dilution using
Rosner's method for univariate models with RDR of 0.46 is 1.95 (95% CI 0.92, 4.22) in the
full sample. The equivalent adjusted estimate for the full stroke sample using the RDR of
0.46 is 1.41 (95% CI 0.58, 3.33), further estimates are presented in Web Table 1.
4 Discussion
Serum MMP-9 levels were positively associated with MI and stroke onset over a 7-year
period in older men and women, but the association was explained by established and novel
risk factors, in particular cigarette smoking, and the inflammatory markers CRP and IL-6. In
the subset with pre-existing CVD the associations of MMP-9 with onset of MI were
somewhat stronger than in those without pre-existing CVD and robust to adjustments.
4.1 Comparison with previous studies
In line with other studies, MMP-9 levels did not vary with age [3,7,19], but were associated
with smoking [3,7,20] and inflammatory markers (including CRP, IL-6, fibrinogen and
white blood cell count) [3,7], but not consistently with other health behaviours [3,7,19],
lipids, blood pressure or BMI [3,7,19]. The finding of a modest association between MMP-9
and MI which was attenuated by risk factor adjustment agrees closely with an earlier study
of the men's cohort at age 40-59 years [7]. The Atherogene study, following patients with
coronary stenosis over 4 years, reported an elevated HR for CVD (1.3 (95% CI 1.1, 1.6) per
quartile increase of MMP-9 after adjusting for established risk factors. As in our study, the
association was completely attenuated after adjustment for inflammatory markers [3]. The
observed attenuation is line with expectation as MMP-9 production may be influenced by
cardiovascular risk factors such as smoking, CRP and IL-6 (which are associated with serum
MMP-9 in our current and previous studies [7] and with plasma MMP-9 in a cross sectional
study [20]. Smaller studies have not reported significant associations between MMP-9 and
CVD, although they may lack power [4,5]. Data from some [3,8,9] studies of the
associations between polymorphisms associated with MMP-9 and CVD-related outcomes
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lend weight to the potential for a causal association between MMP-9 and MI onset.
However, the lack of consistency of the genetic studies caution against this interpretation
[3,10,11]. Our finding that the associations between MMP-9 and MI or stroke did not vary
by gender, smoking status (or indeed age) extends the literature as previous studies have not
investigated such differences. We found some weak suggestive evidence of a stronger
association between MMP-9 and MI in participants with pre-existing CVD. Although
previous studies have not tested this, it fits with evidence from patient populations
suggesting that MMP-9 is associated with CVD-risk, whilst the evidence from healthy
population is weaker. MMP-9 may be a weaker marker of CHD risk in healthy sub-groups
because MMP-9 may be more important in de-stabilizing established plaques rather than
having a directly atherogenic effect. Speculatively, increased expression of MMP-9 (and
decreased expression of tissue inhibitors of MMPs [TIMPS]) may be one way in which
increased circulating inflammatory markers increase the risk of rupture in existing plaques
[1,2] so that MMP-9 could be a biomarker of rupture-prone plaques. Our results however
suggest that MMP-9 is probably too moderately associated with CVD to be clinically useful
biomarker, although it may remain a potential therapeutic target, particularly in individuals
with pre-existing disease.
In relation to stroke, a study of patients with carotid stenosis reported a combined HR for
ipsilateral stroke or cardiovascular death of 1.9 (95% CI 1.1, 3.5) for MMP-9 above vs
below median adjusted for risk factors including smoking [6]. We found no evidence that
MMP-9 is independently associated with onset of stroke, in line with epidemiologic [7] and
genetic data [11].
4.2 Strengths and weaknesses
This study adds to scant prior evidence about the relations of MMP-9 to CVD onset in
generally healthy populations and is the first population-based prospective study of MMP-9
and CVD to investigate gender interactions. The study, which had sufficient size and
statistical power to exclude a relative risk of 1.68 between top and bottom thirds of the
MMP-9 distribution, benefits from validated data about MI and stroke events and
comprehensive data on a range of established and novel cardiovascular risk factors. Few
other studies have prospective data on MMP-9 and subsequent risk of either MI [3,7], or
stroke [6]. The present study has a longer follow-up period and more events than previous
studies in patient populations. One earlier population-based study reported similar results
over a longer follow-up; it was based on a different nested case–control sample of men taken
from the same cohort that provided the nested case–control data presented here, but the
men's MMP-9 measures were from when they were 20 years younger, and the CVD cases
occurred over an earlier period, so the studies have minimal overlap [7]. The results of
stratified analyses suggested that positive associations of MMP-9 with MI may be
particularly strong in subjects with pre-existing CHD. Whilst our study is large in
comparison with previous studies, the wide confidence intervals indicate that we cannot
exclude a modest but potentially important association. This study, like most others, is
limited by having only a single measure of MMP-9. However, we estimated the intra-
individual variability in serum MMP-9 levels. Estimates suggested lower stability of serum
MMP-9 than several established risk factors [16] and after correction for within-person
variability, the ORs for MI and stroke were less conservative and reached conventional
statistical significance. The nested case–control design required that controls survived to the
end of the study which could introduce some bias, however since observed adjusted
associations were modest and not significant, bias is unlikely to be problematic. Response
rates were reasonably high and it is not thought that attrition would affect our estimate of the
association between MMP-9 and CVD, prior work on the men's cohort suggests that non-
attenders did not differ substantially from attenders [21]. Finally, serum samples were used
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in preference to plasma because the MMP-9 ELISA assay was not recommended for plasma
samples due to interfering chelation of EDTA and citrate during the assay process. Some
researchers have suggested that measurement of serum MMP-9 may be problematic for the
interpretation of results, on the basis that levels of MMP-9 are higher in serum than plasma
[22] suggesting platelet and leucocyte degranulation during clotting elevates levels.
However, we like others [23] challenge the assertion that serum MMP-9 measurements are
never physiologically useful. Serum or plasma levels of MMP-9 may not be truly reflective
of MMP-9 concentrations within cellular rupture-prone plaques, which is mechanistically
potentially the most important site of action for MMP-9. However, considering circulating
MMP-9 as a biomarker, serum levels of MMP-9 correlate with both plasma MMP-9 and
with the zymographically measured level of “active circulating” MMP-9 [23,24].
Additionally, in healthy populations, levels of detection of MMP-9 in plasma are very low,
e.g. only 20% of participants free of CHD in Framingham studies had detectable plasma
MMP-9 [19]. This may diminish the statistical power in subsequent data analysis. The
validity of the serum MMP-9 levels, which were measured using standard laboratory
protocols, is supported by the comparability of correlates of serum MMP-9, first with CHD
risk factors [7,10], particularly smoking, and second, the moderate associations with CHD
outcomes are consistent with earlier reports [7,10], finally, serum data are consistent with
data on plasma MMP-9 [3]. Therefore, we see no reason to suppose that, as a biomarker,
serum levels of MMP-9 in a large controlled study are any less relevant than plasma levels,
despite differences in absolute levels detected.
4.3 Implications
MMP-9 was associated with modestly elevated risks of MI and stroke, in large part due to
confounding, particularly by cigarette smoking and inflammation. The confidence limits of
the estimates exclude effects of large magnitude, although any increase in risk of MI or
stroke with increasing MMP-9 could still be modest, even after full adjustment. Our
estimates of measurement imprecision suggest that associations between MMP-9 and CVD
are conservatively estimated. Appreciably larger prospective studies, excluding prevalent
disease and with full adjustments for confounding factors would be necessary to exclude
effects of moderate magnitude. Further large studies could also investigate whether MMP-9
may be a better biomarker of risk among patients with a history of CVD than without, as we
found only weak suggestive evidence and confidence intervals were wide. Our study
suggests that MMP-9 provides little additional information to previously established risk
factors and given inconsistency in findings about MMP-9 and MI, it is unlikely to be useful
in identifying high-risk individuals.
Conflict of interest
None.
References
1. Galis Z.S. Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good,
the bad, and the ugly. Circ Res. 2002; 90:251–262. [PubMed: 11861412]
2. Galis Z.S. Sukhova G.K. Lark M.W. Libby P. Increased expression of matrix metalloproteinases
and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest.
1994; 94:2493–2503. [PubMed: 7989608]
3. Blankenberg S. Rupprecht H.J. Poirier O. Plasma concentrations and genetic variation of matrix
metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003;
107:1579–1585. [PubMed: 12668489]
4. Wu T.C. Leu H.B. Lin W.T. Plasma matrix metalloproteinase-3 level is an independent prognostic
factor in stable coronary artery disease. Eur J Clin Invest. 2005; 35:537–545. [PubMed: 16128859]
Jefferis et al. Page 7
Published as: Atherosclerosis. 2010 February ; 208(2): 557–563.
Sponsored D
ocum
ent 
Sponsored D
ocum
ent 
Sponsored D
ocum
ent
5. Cavusoglu E. Ruwende C. Chopra V. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an
independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart
J. 2006; 151:1101–1108. [PubMed: 16644343]
6. Eldrup N. Gronholdt M.L. Sillesen H. Nordestgaard B.G. Elevated matrix metalloproteinase-9
associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation. 2006;
114:1847–1854. [PubMed: 17030690]
7. Welsh P. Whincup P.H. Papacosta O. Serum matrix metalloproteinase-9 and coronary heart disease:
a prospective study in middle-aged men. QJM. 2008; 101:785–791. [PubMed: 18676684]
8. Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and
outcome. Cardiovasc Res. 2006; 69:636–645. [PubMed: 16122719]
9. Yasmin, McEniery C.M. O'Shaughnessy K.M. Variation in the human matrix metalloproteinase-9
gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol.
2006; 26:1799–1805. [PubMed: 16709939]
10. Hlatky M.A. Ashley E. Quertermous T. Matrix metalloproteinase circulating levels, genetic
polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary
artery disease. Am Heart J. 2007; 154:1043–1051. [PubMed: 18035073]
11. Kaplan R.C. Smith N.L. Zucker S. Matrix metalloproteinase-3 (MMP3) and MMP9 genes and risk
of myocardial infarction, ischemic stroke, and hemorrhagic stroke. Atherosclerosis. 2008;
201:130–137. [PubMed: 18342317]
12. Walker M. Whincup P.H. Shaper A.G. The British Regional Heart Study 1975–2004. Int J
Epidemiol. 2004; 33:1185–1192. [PubMed: 15319395]
13. Lawlor D.A. Bedford C. Taylor M. Ebrahim S. Geographical variation in cardiovascular disease,
risk factors, and their control in older women: British Women's Heart and Health Study. J
Epidemiol Community Health. 2003; 57:134–140. [PubMed: 12540690]
14. Wannamethee S.G. Lowe G.D. Whincup P.H. Physical activity and hemostatic and inflammatory
variables in elderly men. Circulation. 2002; 105:1785–1790. [PubMed: 11956120]
15. Danesh J. Kaptoge S. Mann A.G. Long-term interleukin-6 levels and subsequent risk of coronary
heart disease: two new prospective studies and a systematic review. PLoS Med. 2008; 5:e78.
[PubMed: 18399716]
16. Emberson J.R. Whincup P.H. Morris R.W. Extent of regression dilution for established and novel
coronary risk factors: results from the British Regional Heart Study. Eur J Cardiovasc Prev
Rehabil. 2004; 11:125–134. [PubMed: 15187816]
17. World Health Organization Expert Committee. Hypertension and coronary heart disease:
classification and criteria for epidemiological studies. Geneva: World Health Organization; 1959.
Report no.: 168.
18. Rosner B. Spiegelman D. Willett W.C. Correction of logistic regression relative risk estimates and
confidence intervals for random within-person measurement error. Am J Epidemiol. 1992;
136:1400–1413. [PubMed: 1488967]
19. Sundstrom J. Evans J.C. Benjamin E.J. Relations of plasma matrix metalloproteinase-9 to clinical
cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart
Study. Circulation. 2004; 109:2850–2856. [PubMed: 15173025]
20. Garvin P. Nilsson L. Carstensen J. Circulating matrix metalloproteinase-9 is associated with
cardiovascular risk factors in a middle-aged normal population. PLoS ONE. 2008; 3:e1774.
[PubMed: 18335048]
21. Thomas M.C. Walker M. Lennon L.T. Non-attendance at re-examination 20 years after screening
in the British Regional Heart Study. J Public Health Med. 2002; 24:285–291. [PubMed:
12546205]
22. Gerlach R.F. Demacq C. Jung K. Tanus-Santos J.E. Rapid separation of serum does not avoid
artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin
Biochem. 2007; 40:119–123. [PubMed: 17150202]
23. Thrailkill K. Cockrell G. Simpson P. Physiological matrix metalloproteinase (MMP)
concentrations: comparison of serum and plasma specimens. Clin Chem Lab Med. 2006; 44:503–
504. [PubMed: 16599849]
Jefferis et al. Page 8
Published as: Atherosclerosis. 2010 February ; 208(2): 557–563.
Sponsored D
ocum
ent 
Sponsored D
ocum
ent 
Sponsored D
ocum
ent
24. Wu C.Y. Wu M.S. Chiang E.P. Plasma matrix metalloproteinase-9 level is better than serum
matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res. 2007;
13:2054–2060. [PubMed: 17404086]
Appendix A Supplementary data
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The British Regional Heart Study is a British Heart Foundation (BHF) Research Group and is supported by BHF
programme grant RG/04/003. The British Women's Heart and Health Study is joint funded by the UK Department
of Health and BHF. MMP-9 analyses in participants aged 60–79 years were funded by BHF project grant PG/
07/048. The views expressed in this publication are those of the authors and not necessarily those of the funding
bodies.
Jefferis et al. Page 9
Published as: Atherosclerosis. 2010 February ; 208(2): 557–563.
Sponsored D
ocum
ent 
Sponsored D
ocum
ent 
Sponsored D
ocum
ent
Sponsored D
ocum
ent 
Sponsored D
ocum
ent 
Sponsored D
ocum
ent
Jefferis et al. Page 10
Ta
bl
e 
1
B
as
el
in
e 
ch
ar
ac
te
ris
tic
s (
ag
e 
60
–7
9)
 o
f t
he
 M
I c
as
es
 a
nd
 c
on
tro
ls
 a
nd
 st
ro
ke
 c
as
es
 a
nd
 c
on
tro
ls
: m
ea
n 
(S
D
) o
r n
 (%
)a
.
M
I c
as
es
 (n
 =
 3
68
)
M
I c
on
tr
ol
s (
n 
= 
71
3)
D
iff
er
en
ce
 (p
-v
al
ue
)
St
ro
ke
 c
as
es
 (n
 =
 3
04
)
St
ro
ke
 c
on
tr
ol
s (
n 
= 
59
6)
D
iff
er
en
ce
 (p
-v
al
ue
)
D
em
og
ra
ph
ic
/q
ue
st
io
nn
ai
re
 A
ge
 (y
ea
rs
)
70
.8
3 
(5
.4
6)
70
.8
0 
(5
.4
3)
M
at
ch
ed
71
.3
6 
(5
.3
2)
71
.3
9 
(5
.2
6)
M
at
ch
ed
 M
al
e,
 n
 (%
)
27
0 
(7
3.
4)
51
6 
(7
2.
4)
M
at
ch
ed
19
4 
(6
3.
2)
37
7 
(6
3.
3)
M
at
ch
ed
 N
or
th
er
n 
re
gi
on
 o
f r
es
id
en
ce
, n
 (%
)b
15
6 
(4
2.
4)
29
8 
(4
1.
8)
M
at
ch
ed
11
1 
(3
6.
5)
22
7 
(3
8.
1)
M
at
ch
ed
 N
on
-m
an
ua
l o
cc
up
at
io
n,
 n
 (%
)b
15
5 
(4
4.
5)
32
5 
(4
7.
8)
0.
33
3
12
5 
(4
6.
6)
26
3 
(4
7.
2)
0.
63
2
 P
rio
r e
vi
de
nc
e 
of
 C
V
D
, n
 (%
)
11
1 
(3
0.
2)
11
9 
(1
6.
7)
<0
.0
01
86
 (2
8.
3)
90
 (1
5.
1)
<0
.0
01
 H
is
to
ry
 o
f d
ia
be
te
s, 
n 
(%
)
66
 (1
7.
9)
76
 (1
0.
7)
0.
00
1
43
 (1
4.
1)
73
 (1
2.
3)
0.
42
2
 1
–2
 a
lc
oh
ol
ic
 d
rin
ks
/d
ay
, n
 (%
)
12
9 
(3
8.
2)
30
4 
(4
6.
2)
0.
01
5
12
9 
(3
8.
2)
30
4 
(4
6.
2)
0.
91
3
 C
ur
re
nt
 sm
ok
er
, n
 (%
)
77
 (2
0.
9)
94
 (1
3.
2)
0.
00
2
53
 (1
7.
4)
58
 (9
.8
)
0.
00
2
 P
hy
si
ca
l a
ct
iv
ity
 (i
na
ct
iv
e/
oc
ca
si
on
al
), 
n 
(%
)
23
5 
(6
6.
4)
40
1 
(5
8.
8)
0.
01
7
19
9 
(7
1.
7)
38
3 
(6
6.
8)
0.
21
3
Ph
ys
ic
al
 m
ea
su
re
m
en
ts
 B
od
y 
m
as
s i
nd
ex
 (k
g/
m
2 )
c,d
27
.0
6 
(4
.2
3)
27
.0
2 
(3
.9
6)
0.
93
4
27
.0
6 
(4
.3
3)
27
.0
6 
(4
.0
9)
0.
82
8
 S
ys
to
lic
 b
lo
od
 p
re
ss
ur
e 
(m
m
/H
g)
c,d
,e
15
3.
89
 (2
7.
29
)
14
8.
69
 (2
4.
03
)
0.
00
1
15
4.
32
 (2
4.
96
)
14
9.
37
 (2
4.
42
)
0.
00
5
 D
ia
st
ol
ic
 b
lo
od
 p
re
ss
ur
e 
(m
m
/H
g)
c,d
,e
83
.7
7 
(1
2.
09
)
83
.2
8 
(1
1.
50
)
0.
51
2
84
.9
8 
(1
2.
61
)
82
.4
5 
(1
1.
29
)
0.
00
2
 F
EV
1 (
L/
m
in
)c
,d
,f
2.
15
 (0
.5
5)
2.
23
 (0
.6
0)
0.
02
8
2.
09
 (0
.5
7)
2.
23
 (0
.5
3)
<0
.0
01
Li
pi
ds
/m
et
ab
ol
ic
 m
ar
ke
rs
 T
ot
al
 c
ho
le
st
er
ol
 (m
m
ol
/L
)c
6.
24
 (1
.2
3)
6.
09
 (1
.0
7)
0.
03
2
6.
13
 (1
.2
1)
6.
32
 (1
.1
7)
0.
02
3
 H
D
L 
ch
ol
es
te
ro
l (
m
m
ol
/L
)c
1.
32
 (0
.3
3)
1.
42
 (0
.3
6)
<0
.0
01
1.
43
 (0
.4
0)
1.
43
 (0
.3
6)
0.
92
4
 T
rig
ly
ce
rid
e 
(m
m
ol
/L
)c
,e,
g
1.
80
 (1
.3
1,
 2
.4
1)
1.
58
 (1
.1
3,
2.
09
)
<0
.0
01
1.
64
 (1
.1
1,
 2
.3
2)
1.
69
 (1
.2
3,
 2
.2
9)
0.
46
8
In
fla
m
m
at
or
y 
m
ar
ke
rs
 M
M
P-
9 
(n
g/
m
L)
c,g
52
7 
(3
97
, 7
43
)
50
1 
(3
70
, 7
43
)
0.
09
6
52
2 
(3
63
, 6
73
)
48
7 
(3
93
, 7
04
)
0.
04
5
 C
-r
ea
ct
iv
e 
pr
ot
ei
n 
(m
g/
L)
c,g
2.
39
 (1
.0
5,
 5
.3
9)
1.
77
 (0
.8
9,
 3
.6
2)
<0
.0
01
2.
12
 (1
.0
4,
 4
.3
5)
1.
92
 (0
.9
1,
 4
.1
0)
0.
17
3
Published as: Atherosclerosis. 2010 February ; 208(2): 557–563.
Sponsored D
ocum
ent 
Sponsored D
ocum
ent 
Sponsored D
ocum
ent
Jefferis et al. Page 11
M
I c
as
es
 (n
 =
 3
68
)
M
I c
on
tr
ol
s (
n 
= 
71
3)
D
iff
er
en
ce
 (p
-v
al
ue
)
St
ro
ke
 c
as
es
 (n
 =
 3
04
)
St
ro
ke
 c
on
tr
ol
s (
n 
= 
59
6)
D
iff
er
en
ce
 (p
-v
al
ue
)
 IL
-6
 (p
g/
m
L)
c,e
,g
2.
97
 (1
.9
2,
 4
.0
7)
2.
43
(1
.6
1,
 3
.4
3)
<0
.0
01
2.
83
 (1
.8
7,
 4
.1
4)
2.
56
 (1
.6
5,
 3
.5
5)
0.
02
1
a C
as
e–
co
nt
ro
l s
am
pl
e 
is
 m
ax
im
um
 a
va
ila
bl
e.
b R
ep
or
te
d 
in
 1
97
8–
19
80
 (a
ge
 4
0–
59
 y
ea
rs
) f
or
 m
en
 a
nd
 in
 1
99
8–
20
00
 (a
ge
 6
0–
79
 y
ea
rs
) f
or
 w
om
en
.
c A
dj
us
te
d 
fo
r g
en
de
r, 
ag
e 
an
d 
re
gi
on
 o
f r
es
id
en
ce
 (S
co
tla
nd
, N
or
th
, M
id
la
nd
s a
nd
 S
ou
th
).
d A
dj
us
te
d 
fo
r n
ur
se
 n
um
be
r.
e A
dj
us
te
d 
fo
r t
im
e 
of
 d
ay
.
f A
dj
us
te
d 
fo
r h
ei
gh
t s
qu
ar
ed
.
g A
na
ly
se
d 
as
 n
at
ur
al
 lo
g 
tra
ns
fo
rm
ed
 v
ar
ia
bl
e,
 g
eo
m
et
ric
 m
ea
n 
(I
Q
R
) r
ep
or
te
d 
on
 o
rig
in
al
 sc
al
e.
Published as: Atherosclerosis. 2010 February ; 208(2): 557–563.
Sponsored D
ocum
ent 
Sponsored D
ocum
ent 
Sponsored D
ocum
ent
Jefferis et al. Page 12
Table 2
Association between MMP-9 (tertiles) and cardiovascular risk factors in the MI control sample (n = 713).
Low (10–410) n = 239 Medium (411–599) n = 237 High (600–4496) n = 237 Trend p-valuea
Demographic/questionnaire
 Age (years) 70.81 70.29 71.31 0.310
 Male, n (%) 162 (67.8) 173 (73.0) 181 (73.4) 0.037
 Northern region, n (%)b 90 (37.7) 114 (48.1) 94 (39.7) 0.653
 Non-manual occupation, n (%)b 105 (46.5) 116 (51.3) 104 (45.4) 0.819
 Evidence of CVD, n (%) 40 (16.7) 38 (16.0) 41 (17.3) 0.870
 History of diabetes, n (%) 16 (6.7) 34 (14.4) 26 (11.0) 0.131
 1–2 alcoholic drinks/day, n (%) 102 (47.0) 104 (47.9) 98 (43.8) 0.490
 Current smoker, n (%) 17 (7.11) 27 (11.4) 50 (21.1) <0.001
 Physical activity (inactive/
occasional), n (%)
127 (54.7) 132 (57.9) 142 (64.0) 0.047
Physical measurements
 Body mass index (kg/m2)c,d 26.81 26.99 27.26 0.222
 Systolic blood pressure (mm/
Hg)c,e,d
149.59 147.37 149.03 0.801
 Diastolic blood pressure (mm/
Hg)c,e,d
83.44 82.66 83.72 0.798
 FEV1 (L/min)c,d,f 2.34 2.20 2.14 <0.001
Lipids/metabolic markers
 Total cholesterol (mmol/L)c 6.13 6.09 6.05 0.411
 HDL cholesterol (mmol/L)c 1.44 1.42 1.40 0.219
 Triglyceride (mmol/L)c,e,g 1.55 1.60 1.59 0.562
Inflammatory markers
 C-reactive protein (mg/L)c,g 1.35 1.65 2.48 <0.001
 IL-6 (pg/mL)c,e,g 2.09 2.29 2.86 <0.001
a
Sample (n = 713) MI controls with MMP-9 value. Trend test adjusted for age, gender, region of residence.
b
Reported in 1978–1980 (age 40–59 years) for men and in 1998–2000 (age 60–79 years) for women.
c
Adjusted for gender, age and region of residence (Scotland, North, Midlands and South).
d
Adjusted for nurse number.
e
Adjusted for time of day.
f
Adjusted for height squared.
g
Geometric mean, p-value from linear regression with ln (variable).
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Table 3
Odds ratio (95% CI) of MI in men and women with MMP-9 values in the higher tertiles compared to the lower
tertile of the distribution (i) all participants; (ii) participants without CVD; (iii) participants with pre-existing
CVDa.
MMP-9 MI cases MI controls OR (95% CI) with adjustments
Tertiles n n Model 1 Model 2 Model 3 Model 4
All participants (n = 902)
 Range (ng/mL)
  600–4496 130 209 1.53 (1.09, 2.13) 1.40 (0.99, 1.97) 1.36 (0.96, 1.94) 1.18 (0.81, 1.70)
  411–599 87 192 1.06 (0.74, 1.51) 1.06 (0.74, 1.52) 1.01 (0.70, 1.46) 0.99 (0.68, 1.43)
  10–410 85 199 1 1 1 1
  Total 302 600 p = 0.010 p = 0.049 p = 0.123 p = 0.373
  Continuous: doubling of
(MMP-9)b
302 600 1.20 (0.97, 1.48) 1.13 (0.91, 1.40) 1.11 (0.89, 1.39) 1.01 (0.81, 1.28)
Participants without pre-existing CVD (n = 715)
 Range (ng/mL)
  600–4496 83 176 1.24 (0.84, 1.82) 1.09 (0.71, 1.63) 1.01 (0.67, 1.54) 0.85 (0.55, 1.31)
  411–599 64 158 1.06 (0.71, 1.60) 1.08 (0.73, 1.63) 1.04 (0.68, 1.60) 0.97 (0.63, 1.50)
  10–410 65 176 1 1 1 1
  Total 212 503 p = 0.281 p = 0.671 p = 0.959 p = 0.451
  Continuous: doubling of
(MMP-9)b
212 503 1.11 (0.87, 1.42) 1.03 (0.81, 1.32) 1.01 (0.78, 1.32) 0.89 (0.68, 1.17)
Participants with pre-existing CVD (n = 187)
 Range (ng/mL)
  600–4496 47 33 2.20 (1.04, 4.64) 2.17 (1.00, 4.71) 2.39 (1.05, 5.44) 2.52 (1.08, 5.87)
  411–599 23 34 1.07 (0.48, 2.38) 1.06 (0.47, 2.38) 1.09 (0.47, 2.55) 1.11 (0.47, 2.46)
  10–410 20 30 1 1 1 1
  Total 90 97 p = 0.023 p = 0.034 p = 0.026 p = 0.023
  Continuous: doubling of
(MMP-9)b
90 97 1.28 (0.79, 2.05) 1.23 (0.75, 2.01) 1.20 (0.72, 2.00) 1.21 (0.72, 2.04)
Model 1 = age, gender and region. Model 2 = model 1 + smoking. Model 3 = model 2 + alcohol, physical activity, history of diabetes, BMI, SBP,
DBP, TC, HDL. Model 4 = model 3 + IL-6 + CRP.
a
Complete case analysis sample. Tertiles based on control group. P-value for test for trend over tertiles.
b
OR of MI per 1 log2 increase in log 2(MMP-9) i.e. doubling of MMP-9.
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Table 4
Odds ratio (95% CI) of stroke in men and women with MMP-9 values in the highest compared to lowest
tertile (i) all participants; (ii) participants without CVD; (iii) participants with pre-existing CVDa.
MMP-9 Stroke cases Stroke controls OR (95% CI) with adjustments
Tertiles n n Model 1 Model 2 Model 3 Model 4
All participants (n = 734)
 Range (ng/mL)
  604–2296 89 165 1.36 (0.92, 2.00) 1.29 (0.87, 1.91) 1.17 (0.78, 1.74) 1.09 (0.72, 1.67)
  401–603 82 170 1.20 (0.81, 1.77) 1.17 (0.79, 1.74) 1.11 (0.74, 1.67) 1.08 (0.72, 1.63)
  10–400 66 162 1 1 1 1
  Total 237 497 p = 0.122 p = 0.204 p = 0.462 p = 0.683
  Continuous: doubling of
MMP-9b
237 497 1.24 (0.98, 1.56) 1.20 (0.95, 1.51) 1.14 (0.90, 1.45) 1.10 (0.85, 1.41)
Participants without pre-existing CVD (n = 598)
Range (ng/mL)
  604–2296 65 138 1.48 (0.95, 2.32) 1.42 (0.90, 2.23) 1.30 (0.81, 2.06) 1.22 (0.75, 1.99)
  401–603 59 144 1.30 (0.83, 2.05) 1.28 (0.81, 2.01) 1.25 (0.79, 1.99) 1.22 (0.76, 1.95)
  10–400 46 146 1 1 1 1
  Total 170 497 p = 0.087 p = 0.136 p = 0.283 p = 0.441
  Continuous: doubling of
(MMP-9)b
170 497 1.32 (1.02, 1.72) 1.29 (0.99, 1.68) 1.24 (0.94, 1.63) 1.20 (0.90, 1.60)
Participants with pre-existing CVD (n = 136)
 Range (ng/mL)
  604–2296 24 24 1.00 (0.42, 2.39) 1.01 (0.42, 2.42) 0.86 (0.33, 2.25) 0.77 (0.28, 2.14)
  401–603 23 26 0.89 (0.36, 2.17) 0.89 (0.36, 2.21) 0.87 (0.31, 2.46) 0.83 (0.29, 2.14)
  10–400 20 19 1 1 1 1
  Total 67 69 p = 0.973 p = 0.959 p = 0.765 p = 0.625
  Continuous: doubling of
(MMP-9)b
67 69 0.92 (0.52, 1.62) 0.89 (0.50, 1.58) 0.78 (0.41, 1.49) 0.72 (0.37, 1.42)
Model 1 = age, gender and region. Model 2 = model 1 + smoking. Model 3 = model 2 + SEP, alcohol, physical activity, history of diabetes, history
of CHD, BMI, SBP, DBP, TC, HDL. Model 4 = model 3 + IL-6 + CRP.
a
Complete case analysis sample. Tertiles based on control group. p-value for test for trend over tertiles.
b
OR of MI per 1 log2 increase in log 2(MMP-9) i.e. doubling of MMP-9.
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